SECONDARY CHRONIC MYELOID LEUKEMIA FOLLOWING RADIOACTIVE IODINE (I131)

Objective: Radioactive iodine (RAI) with I131 has an established role in managing differentiated thyroid carcinoma, namely papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma. However, concerns have been raised about its possible carcinogenic effects. Papers of t-CML following I131 ar...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yousef Hailan, Mohamed Yassin
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/991972e454e240f3be96118a92554800
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:991972e454e240f3be96118a92554800
record_format	dspace
spelling	oai:doaj.org-article:991972e454e240f3be96118a925548002021-11-10T04:35:21ZSECONDARY CHRONIC MYELOID LEUKEMIA FOLLOWING RADIOACTIVE IODINE (I131)2531-137910.1016/j.htct.2021.10.1024https://doaj.org/article/991972e454e240f3be96118a925548002021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2531137921011718https://doaj.org/toc/2531-1379Objective: Radioactive iodine (RAI) with I131 has an established role in managing differentiated thyroid carcinoma, namely papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma. However, concerns have been raised about its possible carcinogenic effects. Papers of t-CML following I131 are increasingly reported, and thus this review is dedicated to highlighting it. Methodology: All reports from the 1960s to date related to CML following RAI therapy were searched on Google Scholar and PubMed. Different search terms with Boolean function to search for the relevant articles. Results: We identified ten articles reporting 12 cases, as presented in table 1. We found that most of the reports were for men (8/12) under the age of 60 years (10/12), and the primary tumor was of PTC characteristics (5/12 were PTC, and 3/12 were mixed papillary-follicular carcinoma). The dose of I131 ranged between 30 millicuries (mCi) to 850 mCi; the mean dose was 331 mCi. Also, t-CML developed within the first ten years (9/12), mainly between 4-7 years post-exposure. Conclusion: A few reports found a statistically significant increased risk of leukemia following RAI therapy; some suggested a relative risk of 2.5 for I131 vs. no I131. Observed findings from these studies include a linear relationship between the cumulative dose of I131 and the risk of leukemia, doses higher than 100 mCi were associated with a greater risk of developing secondary leukemia, and most of the leukemias developed within the initial ten years of exposure.Yousef HailanMohamed YassinElsevierarticleDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S38- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Yousef Hailan Mohamed Yassin SECONDARY CHRONIC MYELOID LEUKEMIA FOLLOWING RADIOACTIVE IODINE (I131)
description	Objective: Radioactive iodine (RAI) with I131 has an established role in managing differentiated thyroid carcinoma, namely papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma. However, concerns have been raised about its possible carcinogenic effects. Papers of t-CML following I131 are increasingly reported, and thus this review is dedicated to highlighting it. Methodology: All reports from the 1960s to date related to CML following RAI therapy were searched on Google Scholar and PubMed. Different search terms with Boolean function to search for the relevant articles. Results: We identified ten articles reporting 12 cases, as presented in table 1. We found that most of the reports were for men (8/12) under the age of 60 years (10/12), and the primary tumor was of PTC characteristics (5/12 were PTC, and 3/12 were mixed papillary-follicular carcinoma). The dose of I131 ranged between 30 millicuries (mCi) to 850 mCi; the mean dose was 331 mCi. Also, t-CML developed within the first ten years (9/12), mainly between 4-7 years post-exposure. Conclusion: A few reports found a statistically significant increased risk of leukemia following RAI therapy; some suggested a relative risk of 2.5 for I131 vs. no I131. Observed findings from these studies include a linear relationship between the cumulative dose of I131 and the risk of leukemia, doses higher than 100 mCi were associated with a greater risk of developing secondary leukemia, and most of the leukemias developed within the initial ten years of exposure.
format	article
author	Yousef Hailan Mohamed Yassin
author_facet	Yousef Hailan Mohamed Yassin
author_sort	Yousef Hailan
title	SECONDARY CHRONIC MYELOID LEUKEMIA FOLLOWING RADIOACTIVE IODINE (I131)
title_short	SECONDARY CHRONIC MYELOID LEUKEMIA FOLLOWING RADIOACTIVE IODINE (I131)
title_full	SECONDARY CHRONIC MYELOID LEUKEMIA FOLLOWING RADIOACTIVE IODINE (I131)
title_fullStr	SECONDARY CHRONIC MYELOID LEUKEMIA FOLLOWING RADIOACTIVE IODINE (I131)
title_full_unstemmed	SECONDARY CHRONIC MYELOID LEUKEMIA FOLLOWING RADIOACTIVE IODINE (I131)
title_sort	secondary chronic myeloid leukemia following radioactive iodine (i131)
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/991972e454e240f3be96118a92554800
work_keys_str_mv	AT yousefhailan secondarychronicmyeloidleukemiafollowingradioactiveiodinei131 AT mohamedyassin secondarychronicmyeloidleukemiafollowingradioactiveiodinei131
_version_	1718440580551278592

SECONDARY CHRONIC MYELOID LEUKEMIA FOLLOWING RADIOACTIVE IODINE (I131)

Ejemplares similares